Potential Use of Drug Loaded Nano Composite Pectin Scaffolds for the Treatment of Ovarian Cancer

Author(s): Sarika Chandran, G. Praveen, K.S. Snima, Shantikumar V. Nair, K. Pavithran, Krishnaprasad Chennazhi, Vinoth-Kumar Lakshmanan

Journal Name: Current Drug Delivery

Volume 10 , Issue 3 , 2013

Become EABM
Become Reviewer
Call for Editor


Ovarian cancer is the ninth most common cancer amongst women and ranked as fifth in terms of the cause of cancer related mortality accounting for more deaths than any other cancer of the female reproductive system. Gemcitabine is the most common chemotherapeutic agent used in the treatment of ovarian cancer despite of its disadvantage of having a very lesser half life. In this study, we have envisaged the use of a highly porous, biomimetic and implantable pectin scaffold embedded with gemcitabine loaded fibrin nanoconstructs to improve the half life of the drug, thereby providing localized therapy for ovarian cancer. The controlled and sustained release of the chemokine from the scaffold system was extensively analyzed in vitro different pH environments. The composite scaffolds were found to be highly biocompatible when tested with mammalian cell lines. The excellent cytotoxicity and apoptosis responses induced in ovarian cancer, PA- 1 cell lines proved that the nanocomposite Pectin scaffolds loaded with specific chemokine can be used as implantable “therapeutic wafers” for distracting metastatic cancer cells and thus improve the survival rate of ovarian cancer afflicted individuals.

Keywords: Pectin scaffolds, Fibrin nanoconstructs, Gemcitabine, Drug delivery, Ovarian cancer.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 30 April, 2013
Page: [326 - 335]
Pages: 10
DOI: 10.2174/1567201811310030009
Price: $65

Article Metrics

PDF: 16